ArticleJournal of ginseng research2026
Effects of Korean Red ginseng on the regulation of inflammation, cell death, and fibrosis in a mouse model of rheumatoid arthritis featuring spike protein overexpression.
Article in Journal of ginseng research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: COVID-19 causes inflammation, autoantibody production, and thrombosis-features commonly observed in autoimmune diseases like rheumatoid arthritis (RA). In RA patients infected with COVID-19, immunosuppressive treatments can weaken viral defenses and worsen inflammation. The effects of red ginseng on these patients remain unexplored. We investigated the therapeutic potential of red ginseng extract (RGE) in an RA model with SARS-CoV-2 spike protein overexpression. Materials and methods: Plasmids expressing the SARS-CoV-2 spike protein and ACE2 were delivered into mice with collagen-induced arthritis (CIA). They were orally administered RGE, and effects were assessed via immunohistochemistry, confocal analysis, and ELISA. We analyzed the regulation of Th17 and Treg cells and related cytokines, as well as markers of inflammation, cell death, and fibrosis in splenocytes and fibroblasts. We also examined the combined effects of RGE and methotrexate (MTX). Results: Oral RGE supplementation improved joint inflammation and damage, increasing Treg cells in the spleen. RGE reduced the expression of inflammatory cytokines (IL-17, IL-6, MCP-1, IL-1β, TNF-α), cell death markers (pMLKL, Caspase1), and fibrosis markers (α-SMA, Col1A1) in synovial tissue. In vitro, RGE decreased the expression of these markers in fibroblasts and splenocytes. RGE and MTX had inhibitory effects in the CIA model, with regulatory effects on immune cells, suppressing Th17 cells and enhancing Treg cells. Conclusion: RGE inhibits inflammatory cell death, fibrosis, and modulates immune cells. Its inhibitory effect with MTX suggests therapeutic benefits for RA patients co-infected with COVID-19.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.